Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.74 USD | +3.40% | -3.18% | +9.60% |
05-30 | Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results | CI |
05-15 | Transcript : OncoCyte Corporation, Q1 2024 Earnings Call, May 15, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.60% | 35.42M | |
-38.56% | 8.35B | |
+0.18% | 3.36B | |
+9.29% | 2.52B | |
-18.21% | 2.04B | |
-24.57% | 1.6B | |
+32.37% | 1.18B | |
-7.64% | 707M | |
+8.42% | 704M | |
-29.59% | 532M |
- Stock Market
- Equities
- OCX Stock
- News OncoCyte Corporation
- Oncocyte to Reduce Workforce More Than 40%, Sell 70% Stake in Razor Genomics